Just a few months into a new launch in chronic inflammatory demyelinating polyneuropathy (CIDP), agrenx’s Vyvgart is already making headway in the rare disease space, just one of the long-term growth ...

A blockbuster Argenx therapy now has an additional FDA approval as a treatment for a rare autoimmune disorder affecting nerves, marking the first new treatment for this condition in decades and a new ...

CIDP is a treatable condition that affects the peripheral nervous system. IVIG, plasma exchange, and corticosteroid therapy are the first-line treatment options, but a newer medication for adults has ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a challenge to diagnose even for the most experienced doctors. A major reason: It’s a rare disorder, so not many have seen it. But many ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a serious condition, but it’s treatable. The earlier you’re diagnosed and the earlier you start treatments, the better the chance you’ll ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disease that damages and destroys the nerves in a person’s body. CIDP affects a person’s ability to move, especially ...

CEO Tim Van Hauwermeiren emphasized 2024 as a "phenomenal year," highlighted by expanding the reach of VYVGART to over 10,000 patients globally across three approved indications. He noted the ...

An inability to distinguish between CIDP and POEMS syndrome can negatively affect treatment strategies and outcomes. A 2-step protocol using conduction block and maximum/minimum cross-sectional area ...

The main neuropathy that occurs in diabetes is distal symmetric polyneuropathy (DSPN), but inflammatory neuropathies can also occur Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) may be a rare disease, but it is one of the most common forms of neuropathy and the most common form of chronic autoimmune neuropathy. Roughly ...